http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107217039-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2513-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-119
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
filingDate 2017-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2020-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107217039-B
titleOfInvention Tumor tissue 3D culture method and culture solution
abstract The invention discloses a tumor tissue 3D culture method suitable for various tumor tissues, which comprises the following steps: 1) dropping hydrogel into the pore plate, transferring the cut tumor tissue block into the hydrogel, dropping culture solution and CO 2 Standing in an incubator to solidify the hydrogel; 2) adding a culture solution into the pore plate for culturing, and then taking out and fixing the cultured tumor tissue block; the culture solution comprises the components of Advanced DMEM/F12 culture solution, 1 XGlutaMAX, epidermal growth factor EGF, fibroblast growth factor FGF10, N-acetyl-L-cysteine NAC, prostaglandin E2PGE2, Nicotinamide and 50 XB 27. In addition, the invention also discloses a tumor tissue 3D culture solution. The method is suitable for various tumor tissues, can evaluate the drug effect of the antitumor drug more quickly and accurately, makes up the defects of 2D cell culture and animal experiment evaluation methods, and provides a more convenient and economic model method for clinical drug research and new drug research and development.
priorityDate 2017-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102964591-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID936
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451005606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419480290
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01132
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID461435
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403657
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5988
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590658
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID403045
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID93091914
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID368436
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25313
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13645
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1950
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280360
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487363
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP26224
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12035
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22066175
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01133
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID37455
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425901710
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533858
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA1Z877
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID408035
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323524
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID373313

Total number of triples: 48.